Trial Profile
A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ENLARGE-Lung
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results from NCT03382496 and NCT02910999, describing RW survival outcomes of patients with aNSCLC who resumed nivo after interrupting an initial nivo treatment received as 2+ line-of-therapy presented at the 48th European Society for Medical Oncology Congress
- 26 Apr 2022 Planned End Date changed from 31 May 2024 to 29 Feb 2024.
- 26 Apr 2022 Planned primary completion date changed from 31 Dec 2023 to 29 Feb 2024.